Ladies and gentlemen, thank you for standing by. At this time, I would like to welcome everyone to the Organon Q1 2022 Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. To ask a question during the session, you need to press star one on your telephone. As a reminder, this call is being recorded. Thank you. I would now like to turn the call over to Jennifer Halchak, Vice President, Investor Relations. Please begin your conference. Thank you, Mary, and good morning, everyone. Thank you for joining Organon's Q1 2022 Earnings call. With me today are Kevin Ali, Organon's Chief Executive Officer, who will cover strategy and operational highlights, and Matt Walsh, our Chief Financial Officer, who will review performance, guidance, and capital allocation. Dr. Sandra Milligan, Organon's Head of R&D, will also be joining us for the Q&A portion of this call. Today, we'll be referencing a presentation that will be visible during this call for those of you on our webcast. This presentation will also be available following this call on the Events and Presentation section of our Organon Investor Relations website at www.organon.com. Before we begin, I would like to caution listeners that certain information discussed by management during this Conference Call will include forward-looking statements. Actual results could differ materially from those stated or implied by forward-looking statements due to risks and uncertainties associated with the company's business, which are discussed in the company's filings with the Securities and Exchange Commission, including our 10-K and subsequent periodic filings. In addition, we will discuss certain non-GAAP financial measures on this call, which should be considered as a supplement to and not a substitute for financial measures prepared in accordance with GAAP. A reconciliation of these non-GAAP measures to the comparable GAAP measures is included in the press release and Conference Call presentation. I'd now like to turn the call over to our CEO, Kevin Ali. Good morning, everyone, and thank you, Jen. Welcome to today's call, where we will talk about our Q1 2022 results. For Q1 of 2022, revenue came in at $1.6 billion, up 8% at constant currency, and adjusted EBITDA was $647 million, representing a 41.3% adjusted EBITDA margin. We had a strong Q1. The year is off to a great start, and we are reaffirming the full-year guidance ranges we provided back in February. Now, since our launch almost a year ago, all three of our franchises, women's health, biosimilars, and established brands, have been delivering on their objectives, each playing their important role in creating a sustainable company driving forward our vision of improving the health of women. Let's start with fertility and biosimilars, two of our growth pillars. They continue to grow double- digits in the quarter, and we expect both to deliver double-digits performance for the full- year. We're also very confident in the demand trends we are seeing for Nexplanon that support our view that for the full- year 2022, Nexplanon will perform at least as strongly as the 12% growth at constant currency that we saw in 2021. As we've said in prior calls, some of our products, especially in women's health and biosimilars, are subject to the buying patterns of our institutional customers and will vary quarter- to- quarter. This was evident in Q1 with Nexplanon in the U.S. We had a price increase go into effect in December 2021. As you may recall, we had a very strong Q4 of last year and some volume was pulled forward ahead of that price increase. Demand exiting Q1 was very strong and NEXPLANON is off to a healthy start in Q2 and on track to deliver our expected full-year performance. Organon is continuing to bring renewed focus to NEXPLANON. This includes our digital marketing efforts aimed at raising awareness among consumers and motivating conversations with healthcare providers, all of which are gaining traction and resulting in increased product demand. Other initiatives include unique social media projects and the recent ability to have a telehealth conversation where women can connect with an independent healthcare provider to discuss NEXPLANON and other contraception options. We also continue to evolve our clinical training program offering. In Q1, we trained 6,700 new healthcare professionals to perform the 1-minute insertion and 2-minute removal for NEXPLANON. This is more than triple the number trained in Q1 of last year and well ahead of our pre-pandemic activity. We're also very encouraged about NEXPLANON's growth outside of the U.S. NEXPLANON grew over 30% ex FX outside the U.S., driven by performance in Latin America, which benefited from tender phasing but also increased demand. We are seeing very strong demand in important markets like Brazil, which had a record month in March of this year. Continuing our discussion on women's health, fertility, both in China and the U.S., two very important markets, grew double- digits in the quarter. With women waiting until later in life to have children, the use of assisted reproductive technologies like in vitro fertilization are growing about 5%-10% annually. It is a large market impacting an estimated 190 million people. It is also an industry with significant brand loyalty. Our products, FOLLISTIM, Orgalutran, and Elonva, are well- established and foundational to the patient-friendly GnRH antagonist treatment protocol, which requires fewer injections and is favored in conjunction with egg and embryo freezing. Now let's turn to biosimilars, another growth engine for the company. With about half of our biosimilar business outside of the U.S. and subject to tenders, we will see growth rates vary quarter- to- quarter. We expect biosimilars to continue to deliver double-digits performance on an annualized basis. In the U.S., our two offerings are RENFLEXIS, our infliximab biosimilar, and Ontruzant, our trastuzumab biosimilar. The infliximab market continues to grow every year, and RENFLEXIS has benefited from that tailwind, with sales still growing even five years after launch. The trastuzumab market has some of the highest adoption rates, about 70% among biosimilars, and the uptake of Ontruzant in the U.S. continues to show growth since its launch in 2020. We remain very well- positioned as a commercial collaborator with Samsung, and we are particularly encouraged by the planned U.S. launch of our Humira biosimilar in mid-2023, for which we will be undertaking an interchangeability study. We remain committed to pursuing the sizable biosimilar opportunity presented by an estimated $100 billion plus of blockbuster biologics going off patent over the next decade. We will evaluate these pipeline opportunities with Samsung as well as other biosimilar developers. Equally important to our growth pillars is the stabilization that we are seeing in our Established Brands business. This is a basket of 49 important medicines with significant brand loyalty covering multiple therapeutic areas globally. The potential for this sizable part of Organon's business to stabilize was evident to us well before the spin, and that's what we're seeing now. The LOE risk in this portfolio is now behind us. In addition, by maximizing commercial and lifecycle management opportunities, often at a country level, we believe we can manage this business at a sustained, very low- single-digit erosion rate over the intermediate term. Matt will walk you through some of the favorable one-time items that contributed to the double-digits growth with Established Brands in Q1. Beneath the one-time favorability, the underlying business performed well. In light of the outperformance in Q1 r, we expect Established Brands to deliver close to flat performance for the full- year 2022 on a constant currency basis. Critical to our success in Established Brands is our approach to managing our business in China. Since 2017, we've been focusing our growth strategies on the retail channel, which has been growing double- digits and now represents about half of our Established Brands business in China. There's also strong demand for our products in the hospital channel for those products not yet subject to volume-based procurement, and those products have been growing double- digits as well. China represents a very important market for us, and we're well-positioned there with a solid retail strategy and good revenue diversification. Overall, there was very solid operating performance from the franchises in the quarter, and I'd like to now provide an update on our external growth initiatives. Consistent with our stated commitment to deliver healthcare interventions that address unmet and undermet needs in women's health, we continue to be active on the business development front, expanding our women's health portfolio beyond contraception and fertility. Today, we've been active in clinical stage assets like our licensing of the investigational ebopiprant for preterm labor and our collaboration with our collaboration partner ObsEva and the acquisition of Forendo with assets in development for endometriosis and PCOS. This is balanced against our new commercial stage products like Jada for PPH, Marvelon, and Mercilon, and most recently, our global licensing agreement with Daré Bioscience. Now bacterial vaginosis is the most common cause of vaginitis worldwide. It is estimated to affect 21 million women in the U.S. and can have disruptive symptoms and potentially pose serious health risks. Today, approximately half of the women treated for bacterial vaginosis experience multiple episodes of BV within 12 months of treatment. As evidence of our commitment to the unmet and undermet needs of women, we are licensing Daré XACIATO, which is an FDA-approved medication for the treatment of bacterial vaginosis in women 12 years of age and older. In a phase 3 clinical trial, XACIATO demonstrated improved clinical cure rates as compared to placebo in a one-time dose. We're looking forward to potential Q4 launch of this product in the U.S. The opportunity with Daré is emblematic of our approach to business development. Our goal is to assemble a suite of options that advance women's health with assets that, address unmet needs, including those that may have been overlooked because of patient populations or therapeutic area. Further, we're looking to build a portfolio of assets in various phases of development, from clinical stage with blockbuster potential to already commercialized products. Overall, 2022 is off to a very solid start, and at this point, I'd like to turn it over to Matt to review the quarter in more detail. Thank you, Kevin. As I've done in previous quarters, I'll remind you that our results prior to spin-off are presented on the carve-out basis of accounting, which is a GAAP convention. It's not intended to present results as if Organon were a standalone company. I want to be clear as we discuss our results that because our spin date was June second, it won't be until Q3 of 2022 that we can draw true apples to apples comparisons to prior year results, where all P&L line items represent post-spin standalone financials for Organon. Until that time, revenue is where we'll have the best comparability to prior year periods, and that's where we'll start the financial discussion. Turning to slide seven, revenue for Q3 was $1.6 billion, up 4% as reported and up 8% at constant currency exchange rates when compared to Q1 of last year. In this graphic, we break out the change in revenue according to key drivers, and I'll highlight some of the more significant impacts. The impact of loss of exclusivity, or LOE, during Q1 was approximately $30 million, and it's primarily- related to NuvaRing's LOE in the United States. We didn't have any LOE impact in established brands this quarter. The most significant LOEs facing the portfolio washed out in 2021, and we expect only modest new LOE exposure going forward. Since December of 2020, we have been expecting a generic entry in the U.S. for Dulera. That did not happen in 2021 and has not happened thus far in 2022. Our current expectation is that any potential LOE for Dulera, should it happen this year, will have a limited impact on 2022 results, and that view is currently incorporated into our full- year guidance. Continuing to read across the waterfall chart. In Q1 of last year, the impact from volume-based procurement in China was significant due to the December 2020 implementation of the third round of VBP. Now back then, that was the largest round to that point and included 4 of Organon's products: Singulair Paediatric, Proscar, Propecia, and Arcoxia. That compares with Q1 of this year when there was no new LOE impact from VBP on Organon's products. Moving to volume now, which grew significantly in Q1. The increase in volume came from our growth pillars, fertility, biosimilars, NEXPLANON outside the U.S. this quarter, and China retail, but also from volume growth in our base business and established brands, particularly demand in China for non-VBP brands, as well as for products in Europe and the LATAM region. As Kevin mentioned, some of the favorability in established brands this quarter was due to one-time items. If we think about the 15% FX revenue growth in the quarter for established brands, 18% of that was volume growth, offset by 3% pricing pressure. In that 18% volume growth, it was about evenly split between one-time items and underlying growth in the base business. Given the product and geographic diversity in the established brands franchise, taken alone, none of the one-time items would be needle moving. Just to give you an example of the kind of things that we're talking about, the largest among them was a temporary supply issue currently impacting several competitors in the Japanese market. That drove our performance in Japan this quarter, which compares to weaker performance in Japan in the first quarter of last year when demand was lower due to the expectation that the government was preparing to take action to lower prices. The supply and other bucket primarily represents supply sales to Merck and other third parties, which consist of lower margin sales of pharmaceutical products under contract manufacturing arrangements. For the quarter, supply sales were down about $30 million year-over-year, and that's consistent with our view that we expect volumes under these arrangements to decline. Finally, foreign exchange translation represented about 400 basis points of headwind for this quarter, which is not surprising given the fluctuations in global currency markets and also understanding that approximately 80% of our revenues were derived outside the United States during Q1. Briefly on slide 8, this is where we show geographic distribution of revenue. All of our ex-US regions were nicely ahead of prior year at constant currency. Following up on my earlier comment, here you can see the favorability we had in Japan showing up in the APJ region, the good growth in NEXPLANON and in established brands in Latin America, and the solid performance in China in both established brands and fertility. Now let's take a look at performance by franchise. We'll start with women's health on slide 9. Our women's health business was down 5% as reported and 3% at constant currency in the Q1 versus prior year, driven by a 5% constant currency decline in NEXPLANON and a 6% decline in NuvaRing. Those declines are partially offset by continued strength in fertility led by FOLLISTIM, which improved 20% FX in the quarter. As Kevin mentioned, and as we've explained in prior quarters, NEXPLANON's performance can vary quarter-t o- quarter based on customer buying patterns and tenders. We saw good trends exiting Q1. Q2 is off to a solid start. We continue to expect NEXPLANON to deliver double-digits revenue growth on a constant currency basis for the full- year 2022. Turning to biosimilars on slide 10. Biosimilars grew 22% as reported and 25% FX. We have 5 products in the portfolio, 3 in immunology, and 2 in oncology. RENFLEXIS and Ontruzant are our two largest offerings, and both are offered in the U.S. Globally, RENFLEXIS grew 21% FX in the quarter, driven by continued strong performance in the U.S. Entrezont was up 5%, driven by continued uptake in the U.S. since its launch in July of 2020, and partially offset by competitive pressures in Europe. Turning to established brands now on slide 11. Revenue for established brands was up 10% as reported and 15% FX in Q1. While we did have volume growth in the base business, this should be taken in the context of, first, there was no VBP impact this quarter. Second, there was no LOE in established brands this quarter. Third and final, if you look at slide 5 that Kevin showed earlier, our Established Brands revenue in Q1 of 2021 shows a dip, which made Q1 of last year a favorable comparison point. Some of the prior year dynamic was related to Japan, some was COVID, and some was related to buying patterns of consumers. So as good as the double-digits year-over-year performance looks, the more important comparison point really is how did Established Brands do versus our expectations embedded in the guidance we provided in February. The answer there is quite well and nicely ahead of our expectations. Established Brands getting out of the gate this well in Q1 is what underpins Kevin's comment that we now believe revenue growth in this franchise can get close to flat for 2022 at constant currency, which is better than our estimated longer-term trajectory of low- single-digit erosion. Now turning to our income statement on slide 12. Our GAAP income statement for Q1 is available in our earnings release, and I encourage investors to look at that important information. Here on slide 12, we'll be looking at our non-GAAP income statement for Q1. For gross profit, we're excluding purchase accounting amortization and one-time items- related to the spin-off from our GAAP cost of goods sold. Making these straightforward adjustments, in Q1 of 2022, non-GAAP adjusted gross profit was $1 billion, representing gross margin of 66.5% compared with 62.2% in Q1 of 2021. Again, I'll remind you that at this point in the company's history, it's hard to draw meaningful comparisons because there were pre-spin allocated costs in Q1 of 2021 which were not incurred this year. Viewed through an operating lens, though, we can point to reduced supply sales, which are lower margin compared with product sales as a driver of the year-over-year improvement in gross margin. Adjusted EBITDA margins were 41.3% in Q1 and benefited from the higher gross margin, as well as operating expenses that, due to timing, were at their lowest expected point in this year. I'll speak more about adjusted margins in a moment when we discuss the outlook for the full- year. As we look at debt capitalization and leverage on slide 13, as of March 31, we have bank debt of $9.1 billion netted against cash and cash equivalents of $694 million. Using an LTM EBITDA number that does not adjust for acquired in-process R&D expense per the SEC's recent guidance, our net leverage ratio was approximately 3.6x as of March 31. Our capital allocation priorities remain consistent with past communications. Our first priority, of course, is servicing the dividend, which we're targeting at 20% of free cash flow before one-time items, and which we believe strikes an appropriate balance between reinvesting for growth and delivering near-term value for shareholders. Our second priority is organic growth, which would include lifecycle management opportunities for existing products within our portfolio, supported by capital deployed in our manufacturing plants. On the latter, we expect to see annual capital expenditures in the range of 3%-4% of revenue on an ongoing basis, excluding separation costs. Now, because these first two priorities are not big absorbers of capital, that leaves significant self-generated cash flow for our third capital allocation priority, which I would really say is a tie between execution of external growth plans to develop a new pipeline of new product opportunities. We'll balance that against discretionary debt reduction, just like we did in Q4 of last year. We're committed to maintaining our double-B, Ba2 parent rating, and we will continue to make progress towards a net debt to adjusted EBITDA ratio sustained below 3.5x. Once again, balancing debt reduction with capital deployed for externally sourced growth initiatives. Turning now to guidance on slide fourteen. Here we bridge our expected revenue change year-on-year. The biggest difference on this slide from the version that we showed you in February is the FX translation impact, which has gone from an approximate $100-$200 million or a headwind of 200-300 basis points to an approximate $200-$300 million impact or 300-475 basis point headwind based on where spot rates are today. Operationally, at constant currency, the year is unfolding mostly aligned with our expectations. No significant net changes to the business, and most of the drivers on this page are identical or even slightly better than our original 2022 guidance. With the data that we have at present, we continue to see 2022 revenue within the original guidance range. Although if exchange rates don't improve from where they are today, we would likely be at the lower end of our $6.1-$6.4 billion revenue range. For LOE, we still expect an approximate impact of $100 million, as we communicated last quarter, coming from NuvaRing and a possible generic competitor for Galera in the U.S. As both Kevin and I have reiterated today, 2021 was the last year for which we expected significant LOE revenue impact within our product portfolio. We continue to manage VBP in China, and based on our assumption that VBP rounds 7 and 8 will be implemented later this year, we think that VBP will be an approximate $100 million impact, which is also the same message we communicated last quarter. We expect about $200 million of price erosion in 2022, and that's in line with the historical pricing trends for the global markets that Organon has been selling into for many years. For volume, we're tracking to $600 million-$700 million of growth for the full- year. This important component of our guidance remains unchanged, and it is supported by our Q1 actual performance. The majority of that volume increase is expected to come from multiple growth pillars, Nexplanon, biosimilars, fertility, China retail, and to a lesser extent, recent business development activity. We do expect volume growth in our base business and established brands as well, once again, supported by our Q1 actual results. By the way, we estimate that less than 20% of the volume growth that we're projecting can be attributed to COVID recovery. Turning to other guidance metrics on slide 15, all of which we are affirming today. With regard to adjusted EBITDA margins, looking forward in 2022, the margin favorability we saw in Q1 will be absorbed and balanced downward over the remaining quarters of 2022, with expected increases in operating expenses- related to execution of business development initiatives that'll drive future revenue growth, as well as increased supply chain costs driven by higher energy costs as well as inflation. We expect the impact of increased supply chain costs and inflation will impact all operating expense line items, although mainly the COGS line. Incremental operating expense for completed business development deals will show up primarily in R&D, Forendo is an example of that, and SG&A, where the examples would be launch costs for XACIATO and promotional spending around the reacquisition of Marvelon Mercilon marketing rights in certain Asian countries. As operating expenses build throughout the year, Q4 is expected to be the lowest point for adjusted EBITDA margins. While our range for the full- year is being maintained at 34%-36%, just as I discussed for revenue, if exchange rates remain where they currently are, we need to be looking at the low- end of that range as well for the full- year 2022. Important to our guidance practices going forward and along with other companies in our sector, beginning in 2022, Organon will no longer exclude expenses for in-process R&D from our non-GAAP results. These changes are being made to align with views expressed by the SEC. There were no such expenses in Q1 of this year or last year. The Q3 and Q4 of last year, along with, of course, the full- year 2021, have been recast to reflect these changes and full detail of that recasting can be found in tables 7 and 8 of our press release, as well as in the appendix slides to this earnings presentation. We're not incorporating an estimate of future in-process R&D into our guidance for any business development transactions not yet executed. Our criteria for inclusion will be to have a signed contract. Business development is a strategic priority for us. A future business development activity that involves upfront and/or milestone payments would impact our non-GAAP results and would also impact any guidance we might provide. While we'll work to provide details on those relevant payments when we announce a transaction, we do not plan to update our guidance between quarters based solely on those associated payments alone. Wrapping up the financial discussion, we're off to a solid start to the year. Operationally, the business is performing well with strong demand trends in NEXPLANON, structural tailwinds in fertility, double-digits growth in biosimilars, and the stabilization of the established brands business that we have been signaling for some time. At this point, I'll turn the call back to the operator for questions. Thank you. As a reminder, to ask a question, you will need to press star one on your telephone. To withdraw your question, press the pound key. Again, to ask a question, press star one on your telephone. Our first question comes from the line of Jason Gerberry from BofA. You want to go ahead. Hey, guys. Thanks for taking my questions. Just on biosimilar Humira, can you confirm, do you have a target action date yet for the high- concentration version of the product? You know, what do you hope to benefit from an interchangeability study? I mean, in terms of timing, presumably you're not gonna be first, and by the time you have it, a good chunk of the volume will be in biosimilars. Just curious sort of what you see as the value of running that study. Thanks. Yeah, Jason. Kevin. Good question. In regards to Hadlima, our Humira biosimilar, we are planning to launch in July of next year, so it's rapidly approaching. We've got exciting plans for Hadlima and we think it's gonna be a very important contributor to our future growth. But in regards to interchangeability and the importance of interchangeability, clearly, I think that's one of the many variables that various PBMs are looking at in terms of the fact that those variables being interchangeability, I believe real-world evidence. You know, does this product, this asset been launched in other markets, and how is it doing, and what's the safety and regulatory issues around it? You know, innovative applicator, high- concentration dose is actually being launched, and we have all of that. Now nobody's gonna be coming to the market, Jason, at the time of launch or at the time of LOE of Humira with a perfect profile of what you're looking for. Some may have interchangeability and high citrate-free concentration. others may not have real-world evidence, may not have the type of backbone that we have with Samsung in terms of their production capabilities and excellence in being able to manufacture. We feel very good about the fact that interchangeability will be one of many variables that PBMs are looking for. By the way, probably most important that people are not considering in terms of the biosimilar segment is your relationships with the PBMs. You know, do you have long-term relationships? Is there a lot of trust built up there? Are there long history of being able to work with and develop credibility with these folks? We do. Back to the fact that many of these people that we have in the biosimilar group in the U.S. have been working on these assets since before the days of the spin, for almost a decade now, and have really good relationships with payers in order to be able to get formulary access, which is a key variable in terms of how well you do in the business. Thanks. Mm-hmm. Our next question comes from the line of Terence Flynn from Morgan Stanley. Your line is open. Great. Thanks so much. Maybe 2 questions from me. One, a follow-up on Hadlima. I'm assuming you've already had some preliminary discussions regarding contracting in 2023, so just wondering if you're confident you'll be able to secure a decent piece of the volume, second half of the year, as I think some investors are assuming that biosimilars now really won't be able to participate until 2024 in a meaningful way. That's kinda the first question. Then as you think about, you know, the rest of the year for China, maybe Matt, just remind us what's embedded in your guidance for the outlook there, particularly given some of the rolling lockdowns on the COVID side. Just help us think about any impactors that are already baked into your guidance. Thank you. Yeah, Terrence. I'll start with the first part of your question in regards to Hadlima, the follow on. We believe 2023 is gonna be very busy. There's no doubt. There's quite a few assets coming to the market, quite a few players. We'll be essentially second to market. We do believe that, you know, the way that PBMs are gonna approach this business is not going to be a full wholesale, like a small molecule segment of a shift, but rather, there's gonna be probably, I would guess, 2-3, it depends on the PBM, 2-3 biosimilars on any given formulary. Probably, obviously, the originator will be there as well as a few others. I think the others being, you know, all the variables that I talked about. You know, the citrate-free high- concentration dose, the ultimate interchangeability indication coming down the line, the real world evidence, the unique applicator and so on and so forth. I do believe that probably, you know, PBMs currently as we speak, are working on the 2023 contracts. There will be some volume, but clearly it's going to start to increase, and then in 2024 and beyond, you'll see much more of a penetration. But ultimately getting on formulary is going to be critical in the near term, as we start to come online, and we're very happy that we've got an excellent asset in Hadlima. We've got good relationships with the payers and various PBMs across the country, and we're ready to go. I'll hand it over to Matt to talk about your question regarding second half of business in China. For China, we did not see much of an impact in our business related to COVID lockdowns. We have factored, though, into our forecast for the rest of the year of an impact in Q2, recovery in the latter half of the year. We feel like we've incorporated appropriate consideration for COVID lockdowns in China that can be absorbed within the affirmation of guidance, and we see really on a constant currency basis, China will grow this year. Mm-hmm. Our next question comes from the line of Umer Raffat from Evercore ISI. Your line is open. Hi, this is Eric calling in for Umer. Just had a quick question on the Nexplanon R&D. How is recruitment going for the five-year study? Has COVID slowed down any timelines there? Separately, is Organon planning any trials in other indications like dysmenorrhea or menorrhagia? Hi, Eric. Thanks for the question. With regards to the enrollment for the five-year indication, it's generally on track. We saw about a month slowdown based on the COVID impact, but we're not concerned that we're not gonna bring this in on the previously shared timeline. With regards to additional indications, the team is taking a look at the additional indications right now and formulating our development strategy around our you know our key asset of Nexplanon. Got it. Just the last one on biosimilar growth. You mentioned drivers before in Australia and Brazil. Can you give some more detail on what kind of trends you're seeing there, maybe on uptake or upcoming tender offers? Eric, in regards to. There's two parts that I look at in that question. First of all, as I mentioned, U.S. obviously is gonna be the key market, the key market for our Hadlima, for our Humira biosimilar, as you start to look at our overall biosimilar business footprint across the world. Part of that is the real-world evidence and, as you said, we have Canada, we have Australia as two countries that have been doing very well with ultimately and growing double-digits, strong double-digits with those products. The uptake has been really nicely across all of late 2021 and 2022. We see great movement in those two countries. Now, having said that, back to the real world evidence aspect of it, Biogen, which is a partner of Samsung for Hadlima in Europe, has had long-term experience with Hadlima in Europe, and everything is looking really well in terms of, you know, gaining a sense of confidence by PBMs in the U.S. for this product that we do have quite a bit of experience with this product. Got it. Thank you. Our next question comes from the line of Chris Shibutani from Goldman Sachs. Your line is open. Thank you. Good morning. I wanted to ask two questions relating to the women's health business, particularly to the contraception focus area. Can you comment about the market in general, what you're seeing in terms of U.S. growth, perhaps the share of the LARC in general, and any color as well on contraception broadly about gaining further approvals outside the U.S.? Then within that specific to NEXPLANON, can you talk about some of the metrics further? I think you provided about the U.S. international mix had been shifting from 75/25 to more of a 2/3. How do you see that trending? Then maybe more quantification further that you've also previously provided on what the engagement has been like with your digital marketing and direct-to-consumer. Thank you. Hi, Chris. Thanks for the question. Let me address that first part in terms of the LARC movement in terms of growth. LARCs have been growing worldwide as well as in the U.S., and I think that's a shift a lot of times from the daily pill business segment into LARCs, both in terms of long-acting reversible contraceptives by the way as well as short-acting reversible contraceptives as well, like for example, NuvaRing and others. In regards to how is it going with NEXPLANON? As I mentioned, we had a fantastic Q4 of last year. It was our all-time high. There was a bit of pull forward because we had a price increase in the end of last year. There was a bit of pulling forward in terms of the overall business. That's why we saw a relatively slow January. When I start to look at the February and March and April data, it clearly shows that there's sequential growth month-over-month. We feel that there's very strong signals in terms of sales from distributors to physicians as we, you know, a lot of the business is buy and bill in clinics that is clearly showing a very strong kind of receptivity to some of the things that we're doing, as you mentioned, in terms of the digital media initiatives that we're doing as well as other things that we're engaging in. It's an all-time high in terms of what we've been able to do versus the previous two years in terms of the clinical training program, in terms of all the certifications that we're doing. We are seeing tremendous improvements of, for example, when you mention in terms of Nexplanon.com, our internet site. We have a physician locator exceeded benchmark, almost 32,000 searches out of 58,000 total visitors in Q1. As I mentioned in my initial statements, we started a new telehealth capability at Nexplanon.com in April 2022 to enable women to immediately talk to a healthcare professional about Nexplanon and her contraception offer. We're doing quite a bit in terms of tactically when you talk about rep visits being back to pre-pandemic level, when you talk about clinical training program certification on the 1-minute insertion and 2-minute removal being really at an all-time high since the pre-pandemic phase. When you talk about our digital strategies in regards to the things that we're doing on Nexplanon.com, as well as our social media campaigns, we have really great. I'm very confident that for the year, we'll see the same type of double-digits growth as we saw in last year in 2021. To follow on, you had commented previously that there was about a 20% decline in wellness business, as a proxy perhaps for patients returning to engagement with practitioners on the wellness front that has bearing for NEXPLANON. Any update on what you're seeing trends there? That's a great point, Chris. Let me say this, that number continues to stay to be kind of lingering at around 20% in terms of a reduction of women seeking health visits, health checks. We're hoping that does better over time, that people are able to move forward because remember, though, that there's been an increase in telemedicine. Telemedicine is an increase, and I think that's what's probably taking the place of some of these women who are not going to seek help directly in terms of their health checks. We think that that's kind of stabilizing to the point, in fact, that the pandemic has kind of changed the market dynamics a bit, and I think that there are some women especially who are getting new forms of healthcare that is non-traditional as opposed to what they used to do before in terms of going to the office for those health checks, health visits. Having said that, NEXPLANON continues to do, I think, extremely well because of all the activities that we do. For example, for the whole market, you might see a 20% reduction, but for Nexplanon, we see double-digits growth because we have all-time highs in a number of areas because of the fact that the promise of Organon was really about putting emphasis, support, resourcing, and senior management attention into Nexplanon, and we're starting to see some of the dividends pay off in that in the early phases. Appreciate the commentary. Thank you. Good to talk to you, Chris. Our next question comes from the line of David Amsellem from Piper Sandler. Your line is open. Hey, thanks. Just had a couple of questions. First, just wanted to get your overall thoughts on vertical integration in biosimilars. Obviously you have shared economics here in light of what Viatris did with Biocon. I wanted to just pick your brain on, you know, that model of something that's vertically integrated versus what you are trying to accomplish with, you know, your distribution model and you know, how you see, I guess the wisdom of, you know, what you're doing in terms of your shared economic model in biosims. That's number one. Number two, can you just remind us how you're thinking broadly longer term about the direction of the established brand portfolio ex- US, how you think about, you know, sort of a natural rate of erosion, if you will, in terms of price or, you know, how competitive dynamics come into play, and you know, what's a good way of thinking about erosion longer term for that business? Thank you. Thanks for the question, David. Let me just address the first question in regards to around biosimilars and doing a vertical play there. We are very comfortable both in terms of our relationship with Samsung, which is going almost a decade long, in terms of the way that we perceive our part of the overall business, the business process going forward. Look, I mean, our focus right now is you don't know what really is gonna happen to biosimilars in a decade from now. Things could change in terms of the overall erosion of price, you know, being more aggressive. There are a number of variables out there. We do see this as a very strong opportunistic play, at least for the next 6-10 years. Beyond that, we'll have to see. As a result of where we put our capital allocation, it's really better for us to really focus on our vision, a better and healthier every day for every woman, which is to grow our women's health portfolio. We see opportunities there. We see kind of what I would call responsible valuations in the space. That's where we've done the 5 deals before even being a year old in the market. We see biosimilars as a very important contributor to growth. We also see the opportunity of being very smart in terms of capital allocation and putting it where we see long-term viability of women's health as being a real strong growth player going over for time. Now in regards to the second question of established brands, specifically ex-U.S. business. Look, we saw a phenomenal quarter, but that was predicated on a number of one-time events that were very positive in our favor. If I look at the long-term view, I've had a lot of experience with these products. I've worked with these products for well over 25 years. I know them well, and I knew coming into this spin that with the right type of attention, the right type of resourcing, the right type of focus, entrepreneurial focus, country by country, because there's no single country or single region that has the same level of opportunities, they all vary from one to the other, that this business could go from a very strong erosion pattern, almost double-digits erosion, to actually being flat. Now over the last quarters, the 3 quarters we've proven that. Now given the fact that we've had strong double-digits growth of established brands, two-thirds of our overall company in Q1, that I wanna temper that because of the fact that there was again, some very favorable one-time events. We see some headwinds coming over in the second half of the year that we expected, we planned for things like volume-based procurement, round seven, round eight. Things like for example, pricing for Atozet, our second biggest product in Europe. Things like for example, our annual review that you get in Japan for some of these products. These are some of the pricing headwinds that we factored in. Overall, I am very confident that this year we'll see a flat business overall and potentially if things go our way, it could be slightly better. For the long- term, I would say it would be very low- single- digit erosion, but for the short- term, I would say flat. All right. That's very helpful. Thank you. Thanks, David. Our next question comes from the line of Gregory Fraser from Truist Securities. Great. Thanks for taking the questions. I apologize if you covered this already, but on established brands, how much of that strong growth in Q1 was related to easy comps and the one-time items that you called out versus fundamental drivers that could be more sustainable? On NEXPLANON, do you expect new patient share to be driven primarily by patients switched from daily products or is there an opportunity to take share from IUDs? I'm curious if an IUD is something that might make sense for your portfolio. Thank you. For the first part of your question, established brands for Q1, we had about half and half really. I would say half would be attributable to one-time items, and the other half was just underlying volume growth in the base business. In regards to the second question, with regards to NEXPLANON and where ultimately where we're gonna get our business for in the future. We're really focused on a couple of things. Unintended pregnancies for the last decade has been hovering around 50% worldwide, just south of that in the U.S. in the high 40s. That's clearly an unmet need that needs to be addressed. We do feel that the biggest opportunity we have is from women who are not very happy with pills. Ultimately, the daily compliance issues that continue to lead to unintended pregnancies being way too high. That could be one area. That is definitely gonna be the key area of moving over. I don't think that we're gonna be fighting against other LARCs. I do believe, though, the big opportunities, 'cause we've only got about 10% share worldwide in terms of value and a much lower number in terms of volume. There's a huge runway for us and clearly, COCs or pills are the number one prescribed product out there, and there's clearly a lot of dissatisfaction in a number of communities in terms of women really wanting to have something that's convenient, much higher efficacy rate, and so simple and easy to administer. I think that's really the way that we look at the future of NEXPLANON. Our last question comes from the line of Michael Nedelcovych, Cowen. Cowen, your line is open. Thank you for the question. Another on Hadlima, if you don't mind. Are there any external circumstances that would inhibit Organon from launching Hadlima in 2023? For instance, are you reasonably certain that other IP maybe not contemplated by the contract won't block such a launch? Thank you. Michael, I don't see any issues right now. I think we're late in the game right now, and all those issues have been worked out, in regards to IP challenges and all the things of that nature. I don't see anything right now in my view, that would inhibit us from launching in July of next year. Great. Thank you. There are no further questions at this time. Presenters, you may continue. I'd like to just some concluding remarks. Look, in Organon's short history as an independent company, we've made tremendous progress executing on our state of business objectives from the outset. We have known that the right level of investment and management focus would enable all three of our franchises to reveal their true potential. That is what we are now seeing. Of particular significance is the stabilization of our established brands business. I am delighted with our efforts to unlock the full potential of these brands and to deliver sustained, significant cash flows to fund our vision of a better and healthier every day for every woman. We're well on our way to building a suite of products that address important unmet medical needs in women's health, and our ability to deliver on what we say and remain focused on making a difference for women is what sets Organon apart. Thank you for your time and attention today, and we do look forward to speaking with you throughout the quarter. Thank you very much. This concludes today's Conference Call. Thank you everyone for participating.